AI医疗概念走高 贝瑞基因涨停

Core Viewpoint - The stock of Berry Genomics has reached its daily limit, with other companies in the sector such as Celgen, Chuangyi Huikang, Tigermed, Anbiping, Meinian Health, and BGI also experiencing gains. This surge is linked to the announcement from Insilico Medicine's CEO, Alex Zhavoronkov, regarding the potential market entry of the first drugs entirely conceived by artificial intelligence by 2030 [1] Group 1 - Berry Genomics has hit the daily trading limit, indicating strong market interest and investor confidence [1] - Other companies in the healthcare and biotechnology sector, including Celgen, Chuangyi Huikang, Tigermed, Anbiping, Meinian Health, and BGI, have also seen their stock prices rise in response to the news [1] - Insilico Medicine's CEO has projected that the first AI-conceived drugs could be available by 2030, highlighting the growing role of artificial intelligence in drug development [1]